Lobbying Filing Details

Total Spending

$680,000

Activities

3

Lobbyists

3

Gov't Entities

6

Filing Information
Filing UUID:
cd489f72-368f-42e5-81cb-c09e84d911ec
Type:
Q2 - 2nd Quarter - Report
Period:
2016 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 20, 2016 at 8:12 PM
Income:
$0
Expenses:
$680,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Mary-Lacey Reuther
Registrant
ASTELLAS PHARMA US, INC.

Pharmaceuticals

Northbrook, Illinois
Client
ASTELLAS PHARMA US, INC.
Illinois, United States of America
Lobbying Activities (3)
Activity 1
Copyright/Patent/Trademark

Issues related to various patent reform bills (H.R.9, S.632, S.1137).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medicare/Medicaid

Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.